ReviewPurinergic signalling2026
The role and therapeutic potential of purinergic signaling pathway in metabolic syndrome-related atherosclerosis.
Review in Purinergic signalling, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metabolic syndrome (MetS) is a cluster of interrelated and co-occurring metabolic disorders, including abdominal obesity, hyperglycemia, dyslipidemia, the reduced high-density lipoprotein (HDL) cholesterol, and/or hypertension. Cardiovascular diseases are the leading causes of death and disability in metabolic syndrome. Each component of MetS is an independent risk factor for cardiovascular diseases, and the combination of these factors can increase the incidence and severity of cardiovascular diseases, such as atherosclerosis, myocardial infarction, and heart failure, with atherosclerosis being the primary cause of cardiovascular-related death in MetS. The specific pathogenic mechanism in the occurrence and development of atherosclerosis in MetS is still not fully understood. An increasing number of studies have shown that the purinergic signaling pathway plays a significant role in atherosclerosis. ATP and ADP, key signaling molecules in the purinergic signaling pathway, are not only involved in cellular energy metabolism but also activate the purinergic signaling pathway by binding to P1 and P2 purinergic receptors (P1R and P2R), regulating vascular contraction and relaxation, and inhibiting platelet aggregation. Purinergic signaling can act as both a promoter and a resistance factor in the formation of atherosclerosis, depending on the receptor subtype and downstream signaling network. This review summarizes the specific roles and mechanisms of the purinergic signaling network in MetS-related atherosclerosis and analyzes the clinical application of targeting the purinergic signaling pathway, providing a theoretical basis and innovative ideas for basic research and clinical treatment in this field.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.